Get the Stockscreener App
1.82
10.28%
-0.20
Genprex Inc stock is traded at $1.82, with a volume of 1.13M.
It is down -10.28% in the last 24 hours and up +416.91% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$2.02
Open:
$2
24h Volume:
1.13M
Relative Volume:
0.13
Market Cap:
$4.91M
Revenue:
-
Net Income/Loss:
$-31.45M
P/E Ratio:
-2.9355
EPS:
-0.62
Net Cash Flow:
$-24.56M
1W Performance:
-25.73%
1M Performance:
+416.91%
6M Performance:
-25.73%
1Y Performance:
-85.80%
1-Day Range:
$1.76
$2.08
1-Week Range:
$1.76
$2.59
52-Week Range:
$0.2806
$335.84
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting - PR Newswire
Genprex Announces Sponsored Research Agreement with The Universi - GuruFocus.com
Short Interest in Genprex, Inc. (NASDAQ:GNPX) Increases By 5.2% - Defense World
Investor Excitement Sparks Genprex (GNPX) Stock Rally - Stocks Telegraph
Genprex to Participate in 2024 BIO Europe Conference - Nasdaq
Genprex reports positive preclinical gene therapy data By Investing.com - Investing.com South Africa
Genprex reports positive preclinical gene therapy data - Investing.com India
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma - PR Newswire
Genprex (NASDAQ:GNPX) Announces Sponsored Research Agreement with University of Michigan Rogel Cancer Center for Study on TUSC2 Gene Therapy in ALK-Positive Lung Cancer Patients - Defense World
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.80% - MSN
Genprex explores gene therapy in lung cancer study - Investing.com India
Genprex explores gene therapy in lung cancer study By Investing.com - Investing.com South Africa
Genprex signs two lung cancer research agreements - TipRanks
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive - StreetInsider.com
3 Penny Stocks to Watch Now, 10/24/24 - TipRanks
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.02% - MSN
2 No-Brainer Artificial Intelligence (AI) Stocks to Buy Right Now - Yahoo Finance
Dow Falls Over 150 Points; General Motors Tops Q3 Views - Benzinga
‘Permanent should mean Permanent’: Purbeck calls for commitment to Full Expensing - Yahoo! Voices
TD Bank becomes liquidity provider for LTX - Yahoo! Voices
UK economy 'set to accelerate', says IMF - Yahoo! Voices
IMF's economic view: A brighter outlook for US but still-tepid global growth - Yahoo! Voices
Scotch whisky business Compass Box in overseas push - Yahoo News
Siemens secures contract to optimise Unibuss’ electric fleet with Depot360 - Yahoo! Voices
US dough business Urban Farmer appoints Chris Jaromin as new CEO - Yahoo! Voices
DHL Supply Chain to close Canal Winchester warehouse, lay off more than 150 workers - Yahoo News
QC Copper to acquire remaining 50% of Roger Gold-Copper Project - Yahoo! Voices
CAC introduces cyber cover for energy and utility sectors - Yahoo! Voices
How small Canadian retailers are thriving on multiple sales channels - Yahoo! Voices
Zymeworks doses first subject in Phase I trial of ZW171 for various forms of cancer - Yahoo! Voices
2 Low-Cost Vanguard ETFs for Set-and-Forget Investors - Yahoo! Voices
Eleven unveils AI-driven software tailored for accounting - Yahoo News
Excelsior gets final permit for Arizona copper mine operations - Yahoo News
The Dean Group acquires 280-room Roomer’s Munich hotel - Yahoo! Voices
JCP urges Cheesecake to spin off three brands for growth - Yahoo! Voices
Kmart just closed its last full store — but there’s still a location in Kendall - Yahoo! Voices
These Are the 5 Most Shorted Stocks in the S&P 500 Index. The Bears Are Wrong About 1 of Them. - Yahoo! Voices
This Big Social Security Change Was Just Announced, and It Will Affect Your 2025 Benefits - Yahoo! Voices
HSBC splits up bank amid growing tensions between China and the West - Yahoo! Voices
Shari's Cafe & Pies appears to close all remaining Oregon locations - Yahoo! Voices
UK plans to ease ring-fencing regulations for banks to boost competitiveness - Yahoo! Voices
Rothschild & Co leads M&A financial advisory in Middle East & Africa for Q1-Q3 2024 - Yahoo! Voices
Allen & Overy leads M&A legal advisory in Middle East & Africa in Q1-Q3 2024 - Yahoo! Voices
This discount chain is leaving the Kansas City area for good. Sales go until it’s gone - Yahoo! Voices
Benchmark is raising $170M for its latest partners-only fund - Yahoo! Voices
AI Game-Changer? Lumen Surge 10% After Strategic Deal with Meta - Yahoo
Thermo Fisher’s Oncomine gains FDA approval as brain tumor diagnostic - Yahoo! Voices
Wall Street-Heavily Traded - WDRB
Analysts’ Revisions Show Improving Sentiment For Comcast Corp (NASDAQ: CMCSA) - Stocks Register
What Did We Note About Insider Trading At Shoals Technologies Group Inc (NASDAQ: SHLS)? - Stocks Register
How Do Things Look For Genprex Inc (NASDAQ: GNPX) In The Short-Term? - Stocks Register
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):